What one share of Nervgen Pharma holds
On February 14, 2023, we announced that we had completed dosing of all subjects in the NVG-291 Phase 1 clinical trial and that we planned to initiate a Phase 1b/2a clinical trial of NVG-291 in individuals with SCI in Q3 2023.
Nervgen Pharma’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.44 |
|---|---|
| Cash and investments | $0.20 |
| Book value | $0.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.26 | — | — | — | $0.03 |
| 2025 | — | −$0.44 | — | — | — | $0.03 |
Common questions about Nervgen Pharma
How much does one share of Nervgen Pharma earn?
Over its latest fiscal year, Nervgen Pharma lost $0.44 for each share.
Does Nervgen Pharma pay a dividend?
Nervgen Pharma didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Nervgen Pharma’s book value per share?
Nervgen Pharma’s book value is $0.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Nervgen Pharma have?
Each share of Nervgen Pharma has $0.20 of cash and investments, as of December 31, 2025.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.